© 2022 © 2020 Genprex Inc. All Rights Reserved.
Proceeds will add resources for the Company’s Acclaim-1 and Acclaim-2 clinical trials in lung cancer, as well as its pre-clinical programs in cancer and diabetes
Genprex has entered into a securities purchase agreement with a single healthcare-dedicated institutional investor for the purchase and sale of 3,116,884 shares of its common stock at a purchase price of $3.85 per share in a registered direct offering priced at-the-market under Nasdaq rules.
Major Manufacturing Milestone Positions the Company for Success In the Lung Cancer Therapeutics Market, Expected to Grow to $26.3 Billion by 2023
Successful Completion of Engineering Batch with Transfer from Research Institution to Commercial Contract Development and Manufacturing Organizations with Clinical Production Underway
Presentation to Highlight the Company’s Recent Progress on its Upcoming Acclaim-1 Clinical Trial for the Treatment of Non-Small Cell Lung Cancer